Challenges for molecular neuroimaging with MRI

Magnetic resonance (MRI)‐based molecular imaging methods are beginning to have impact in neuroscience. A growing number of molecular imaging agents have been synthesized and tested in vitro, but so far relatively few have been validated in the brains of live animals. Here, we discuss key challenges associated with expanding the repertoire of successful molecular neuroimaging approaches. The difficulty of delivering agents past the blood‐brain barrier (BBB) is a particular obstacle to molecular imaging in the central nervous system. We review established and emerging techniques for trans‐BBB delivery, including intracranial infusion, BBB disruption, and transporter‐related methods. Improving the sensitivity with which MRI‐based molecular agents can be detected is a second major challenge. Better sensitivity would in turn reduce the requirements for delivery and alleviate potential side effects. We discuss recent efforts to enhance relaxivity of conventional longitudinal relaxation time (T1) and transverse relaxation time (T2) MRI contrast agents, as well as strategies that involve amplifying molecular signals or reducing endogenous background influences. With ongoing refinement of imaging approaches and brain delivery methods, MRI‐based techniques for molecular‐level neuroscientific investigation will fall increasingly within reach. © 2010 Wiley Periodicals, Inc. Int J Imaging Syst Technol, 20, 71–79, 2010

[1]  A. Pines,et al.  Gas flow MRI using circulating laser-polarized 129Xe. , 1999, Journal of magnetic resonance.

[2]  Ralph Weissleder,et al.  A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. , 2003, Molecular imaging.

[3]  Bruce R. Rosen,et al.  Imaging Cerebral Gene Transcripts in Live Animals , 2007, The Journal of Neuroscience.

[4]  M. Botta,et al.  Dendrimeric gadolinium chelate with fast water exchange and high relaxivity at high magnetic field strength. , 2005, Journal of the American Chemical Society.

[5]  Vikram D Kodibagkar,et al.  19F: a versatile reporter for non-invasive physiology and pharmacology using magnetic resonance. , 2005, Current medicinal chemistry.

[6]  C. Olanow,et al.  Manganese‐Induced Parkinsonism and Parkinson's Disease , 2004, Annals of the New York Academy of Sciences.

[7]  M. Thaning,et al.  Real-time metabolic imaging. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[8]  E. Neuwelt,et al.  Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. , 1998, Neurosurgery.

[9]  K. Messmer,et al.  Reduction of post-traumatic intracranial hypertension by hypertonic/hyperoncotic saline/dextran and hypertonic mannitol. , 1995, Neurosurgery.

[10]  J. Trojanowski,et al.  In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease , 2000, Neurobiology of Aging.

[11]  Pernille R. Jensen,et al.  Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate , 2008, Nature.

[12]  Po-Chun Chu,et al.  Magnetic resonance imaging enhanced by superparamagnetic iron oxide particles: Usefulness for distinguishing between focused ultrasound‐induced blood–brain barrier disruption and brain hemorrhage , 2009, Journal of magnetic resonance imaging : JMRI.

[13]  Enzo Terreno,et al.  Pushing the Sensitivity Envelope of Lanthanide-Based Magnetic Resonance Imaging (MRI) Contrast Agents for Molecular Imaging Applications , 2009 .

[14]  Natalia Vykhodtseva,et al.  Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. , 2008, Ultrasonics.

[15]  Stephen R. Thomas,et al.  Magnetic resonance imaging of rat brain following in vivo disruption of the cerebral vasculature , 1991, Brain Research Bulletin.

[16]  Gunnar P. H. Dietz,et al.  Delivery of bioactive molecules into the cell: the Trojan horse approach , 2004, Molecular and Cellular Neuroscience.

[17]  L. Bakay,et al.  Ultrasonically produced changes in the blood-brain barrier. , 1956, A.M.A. archives of neurology and psychiatry.

[18]  S. Capuani,et al.  In vivo 19F MRI and 19F MRS of 19F-labelled boronophenylalanine–fructose complex on a C6 rat glioma model to optimize boron neutron capture therapy (BNCT) , 2008, Physics in medicine and biology.

[19]  Peter Caravan,et al.  Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents. , 2009, Contrast media & molecular imaging.

[20]  R S Balaban,et al.  A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). , 2000, Journal of magnetic resonance.

[21]  Robert J Gillies,et al.  High resolution pHe imaging of rat glioma using pH‐dependent relaxivity , 2006, Magnetic resonance in medicine.

[22]  Alan Koretsky,et al.  Micro-engineered local field control for high-sensitivity multispectral MRI , 2008, Nature.

[23]  W. Pardridge The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[24]  Nobuhisa Iwata,et al.  19F and 1H MRI detection of amyloid beta plaques in vivo. , 2005, Nature neuroscience.

[25]  R Weissleder,et al.  High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. , 1999, Bioconjugate chemistry.

[26]  J. Huwyler,et al.  Brain drug delivery of small molecules using immunoliposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Erkki Ruoslahti,et al.  Proteolytic actuation of nanoparticle self-assembly. , 2006, Angewandte Chemie.

[28]  Zahi A Fayad,et al.  Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): Sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1.5T and 3T , 2006, Magnetic resonance in medicine.

[29]  E. Hoffman,et al.  Application of annihilation coincidence detection to transaxial reconstruction tomography. , 1975, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  Enzo Terreno,et al.  NMR relaxometric studies of Gd(III) complexes with heptadentate macrocyclic ligands , 1998 .

[31]  Keren Ziv,et al.  MRI detection of transcriptional regulation of gene expression in transgenic mice , 2007, Nature Medicine.

[32]  W. Cacheris,et al.  The relationship between thermodynamics and the toxicity of gadolinium complexes. , 1990, Magnetic resonance imaging.

[33]  W. Pardridge,et al.  Delivery of β-Galactosidase to Mouse Brain via the Blood-Brain Barrier Transferrin Receptor , 2005, Journal of Pharmacology and Experimental Therapeutics.

[34]  Rika Takikawa,et al.  [In-vivo visualization of gene expression using magnetic resonance imaging]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[35]  E. Ahrens,et al.  A new transgene reporter for in vivo magnetic resonance imaging , 2005, Nature Medicine.

[36]  K. Raymond,et al.  High-relaxivity MRI contrast agents: where coordination chemistry meets medical imaging. , 2008, Angewandte Chemie.

[37]  P C Lauterbur,et al.  Progress in n.m.r. zeugmatography imaging. , 1980, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[38]  Thomas J Meade,et al.  New magnetic resonance contrast agents as biochemical reporters , 2003, Current Opinion in Neurobiology.

[39]  Mikhail G. Shapiro,et al.  Protein nanoparticles engineered to sense kinase activity in MRI. , 2009, Journal of the American Chemical Society.

[40]  E.,et al.  Paramagnetic Metal Complexes as Water Proton Relaxation Agents for NMR Imaging : Theory and Design , 2001 .

[41]  Xiaoping Hu,et al.  MagA is sufficient for producing magnetic nanoparticles in mammalian cells, making it an MRI reporter , 2008, Magnetic resonance in medicine.

[42]  Natalia Vykhodtseva,et al.  Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI‐guided focused ultrasound , 2007, International journal of cancer.

[43]  J. Kreuter,et al.  Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.

[44]  E. Frenkel,et al.  Successful treatment of primary central nervous system lymphomas with chemotherapy after osmotic blood-brain barrier opening. , 1983, Neurosurgery.

[45]  Jinwoo Cheon,et al.  Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging , 2007, Nature Medicine.

[46]  Scott E. Fraser,et al.  A SMART MAGNETIC RESONANCE IMAGING AGENT THAT REPORTS ON SPECIFIC ENZYMATIC ACTIVITY , 1997 .

[47]  N. Sibson,et al.  Systemic Inflammatory Response Reactivates Immune-Mediated Lesions in Rat Brain , 2009, The Journal of Neuroscience.

[48]  G. Barnett,et al.  Perioperative Complications of Blood Brain Barrier Disruption Under General Anesthesia: A Retrospective Review , 2008, Journal of neurosurgical anesthesiology.

[49]  Robert E Lenkinski,et al.  PARACEST agents: modulating MRI contrast via water proton exchange. , 2003, Accounts of chemical research.

[50]  John M Pauly,et al.  Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles , 2005, Magnetic resonance in medicine.

[51]  E. Kanal,et al.  Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. , 2007, Radiology.

[52]  Z. Ram,et al.  Convection-enhanced delivery of maghemite nanoparticles: Increased efficacy and MRI monitoring. , 2008, Neuro-oncology.

[53]  A. Blamire,et al.  MRI detection of early endothelial activation in brain inflammation , 2004, Magnetic resonance in medicine.

[54]  Christian Hilty,et al.  Molecular Imaging Using a Targeted Magnetic Resonance Hyperpolarized Biosensor , 2006, Science.

[55]  Satya V. Chandra,et al.  Role of iron deficiency in inducing susceptibility to manganese toxicity , 1976, Archives of Toxicology.

[56]  Ralph Weissleder,et al.  Magnetic nanoparticles for MR imaging: agents, techniques and cardiovascular applications , 2008, Basic Research in Cardiology.

[57]  R. Lauffer,et al.  Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.

[58]  A. Pines,et al.  Spectrally resolved magnetic resonance imaging of a xenon biosensor. , 2005, Angewandte Chemie.

[59]  P. Choyke,et al.  Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. , 2008, Nanomedicine.

[60]  E. Neuwelt,et al.  Imaging, Distribution, and Toxicity of Superparamagnetic Iron Oxide Magnetic Resonance Nanoparticles in the Rat Brain and Intracerebral Tumor , 2005, Neurosurgery.

[61]  B. Sitharaman,et al.  Gadonanotubes as new high-performance MRI contrast agents , 2006, International journal of nanomedicine.

[62]  Alan Jasanoff,et al.  MRI contrast agents for functional molecular imaging of brain activity , 2007, Current Opinion in Neurobiology.

[63]  S. Maier,et al.  Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring. , 2005, Cancer research.

[64]  A Dean Sherry,et al.  Chemical exchange saturation transfer contrast agents for magnetic resonance imaging. , 2008, Annual review of biomedical engineering.

[65]  Piotr Walczak,et al.  Artificial reporter gene providing MRI contrast based on proton exchange , 2007, Nature Biotechnology.

[66]  Natalia Vykhodtseva,et al.  Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. , 2006, Journal of neurosurgery.

[67]  H. Lee,et al.  Imaging Brain Amyloid of Alzheimer Disease in Vivo in Transgenic Mice with an Aβ Peptide Radiopharmaceutical , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[68]  Weihong Tan,et al.  TAT conjugated, FITC doped silica nanoparticles for bioimaging applications. , 2004, Chemical communications.

[69]  T. Meade,et al.  Cellular delivery of MRI contrast agents. , 2004, Chemistry & biology.

[70]  Hellmut Merkle,et al.  Manganese‐enhanced magnetic resonance imaging of mouse brain after systemic administration of MnCl2: Dose‐dependent and temporal evolution of T1 contrast , 2005, Magnetic resonance in medicine.

[71]  W. Hacke,et al.  Effects of hypertonic saline hydroxyethyl starch solution and mannitol in patients with increased intracranial pressure after stroke. , 1998, Stroke.

[72]  D. Tank,et al.  Brain magnetic resonance imaging with contrast dependent on blood oxygenation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[73]  Jide Xu,et al.  Syntheses and relaxation properties of mixed gadolinium hydroxypyridinonate MRI contrast agents. , 2000, Inorganic chemistry.

[74]  E. Bell,et al.  Progress and problems in the neurological applications of focused ultrasound. , 1960, Journal of neurosurgery.

[75]  Assaf A Gilad,et al.  MRI Reporter Genes , 2008, Journal of Nuclear Medicine.

[76]  R. Muller,et al.  Nuclear magnetic relaxation dispersion studies of water‐soluble gadolinium(iii)‐texaphyrin complexes , 1995, Journal of magnetic resonance imaging : JMRI.

[77]  R Weissleder,et al.  MR imaging and scintigraphy of gene expression through melanin induction. , 1997, Radiology.

[78]  Anna Moore,et al.  In vivo imaging of siRNA delivery and silencing in tumors , 2007, Nature Medicine.

[79]  W. Pardridge Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. , 2008, Bioconjugate chemistry.

[80]  Anders M. Dale,et al.  Repeated fMRI Using Iron Oxide Contrast Agent in Awake, Behaving Macaques at 3 Tesla , 2002, NeuroImage.

[81]  Peter Magnusson,et al.  13C imaging—a new diagnostic platform , 2005, European Radiology.

[82]  T. Ng,et al.  T1 and T2 relaxivities of succimer-coated MFe23+O4 (M=Mn2+, Fe2+ and Co2+) inverse spinel ferrites for potential use as phase-contrast agents in medical MRI , 2009 .

[83]  M. Botta,et al.  High relaxivity gadolinium hydroxypyridonate-viral capsid conjugates: nanosized MRI contrast agents. , 2008, Journal of the American Chemical Society.

[84]  T. Davis,et al.  The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.

[85]  Manabu Kinoshita,et al.  Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[86]  Alexander Petrovsky,et al.  Oligomerization of Paramagnetic Substrates Result in Signal Amplification and Can be Used for MR Imaging of Molecular Targets , 2002, Molecular imaging.

[87]  Kathryn Sharer,et al.  In vivo detection of single cells by MRI , 2006, Magnetic resonance in medicine.

[88]  Effects of Gd‐DTPA after Osmotic BBB Disruption in a Rodent Model: Toxicity and MR Findings , 1994, Journal of computer assisted tomography.

[89]  W. Pardridge Blood-brain barrier drug targeting: the future of brain drug development. , 2003, Molecular interventions.

[90]  N. Sibson,et al.  Glyconanoparticles allow pre-symptomatic in vivo imaging of brain disease , 2009, Proceedings of the National Academy of Sciences.

[91]  R. Gillies,et al.  Responsive MRI agents for sensing metabolism in vivo. , 2009, Accounts of chemical research.

[92]  Afonso C. Silva,et al.  In vivo neuronal tract tracing using manganese‐enhanced magnetic resonance imaging , 1998, Magnetic resonance in medicine.

[93]  F. Prato,et al.  Magnetic Resonance Imaging of Cells Overexpressing MagA, an Endogenous Contrast Agent for Live Cell Imaging , 2009, Molecular imaging.

[94]  J. Ardenkjær-Larsen,et al.  Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[95]  Brandon D. Armstrong,et al.  Hyperpolarized water as an authentic magnetic resonance imaging contrast agent , 2007, Proceedings of the National Academy of Sciences.

[96]  W. Pardridge Drug Targeting to the Brain , 2007, Pharmaceutical Research.

[97]  M. Fukunaga,et al.  Dynamic activity‐induced manganese‐dependent contrast magnetic resonance imaging (DAIM MRI) , 2002, Magnetic resonance in medicine.

[98]  Peter Caravan,et al.  Synthesis and evaluation of a high relaxivity manganese(II)-based MRI contrast agent. , 2004, Inorganic chemistry.

[99]  Sophie Laurent,et al.  Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. , 2006, Contrast media & molecular imaging.

[100]  Sophie Laurent,et al.  Magnetic resonance imaging of inflammation with a specific selectin‐targeted contrast agent , 2005, Magnetic resonance in medicine.

[101]  J. Gore,et al.  Noninvasive Detection of Matrix Metalloproteinase Activity In Vivo using a Novel Magnetic Resonance Imaging Contrast Agent with a Solubility Switch , 2007, Molecular imaging.

[102]  Samuel A Wickline,et al.  In vivo “hot spot” MR imaging of neural stem cells using fluorinated nanoparticles , 2008, Magnetic resonance in medicine.

[103]  J. Bulte,et al.  New “multicolor” polypeptide diamagnetic chemical exchange saturation transfer (DIACEST) contrast agents for MRI , 2008, Magnetic resonance in medicine.

[104]  G L Wolf,et al.  Cardiovascular toxicity and tissue proton T1 response to manganese injection in the dog and rabbit. , 1983, AJR. American journal of roentgenology.

[105]  Ferenc A. Jolesz,et al.  Local and reversible blood–brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications , 2005, NeuroImage.

[106]  Antony K. Chen,et al.  Superparamagnetic Iron Oxide Nanoparticle Probes for Molecular Imaging , 2006, Annals of Biomedical Engineering.

[107]  Eric T Ahrens,et al.  Enhanced positive‐contrast visualization of paramagnetic contrast agents using phase images , 2009, Magnetic resonance in medicine.

[108]  Ralph Weissleder,et al.  Intracellular cargo delivery using tat peptide and derivatives , 2004, Medicinal research reviews.

[109]  D. Turnbull,et al.  In vivo auditory brain mapping in mice with Mn-enhanced MRI , 2005, Nature Neuroscience.

[110]  S A Small,et al.  Spatio-temporal analysis of molecular delivery through the blood–brain barrier using focused ultrasound , 2007, Physics in medicine and biology.

[111]  S. Rapoport,et al.  Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. , 1984, Federation proceedings.

[112]  Ralph Weissleder,et al.  Emerging concepts in molecular MRI. , 2007, Current opinion in biotechnology.

[113]  K. Hynynen,et al.  Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. , 2001, Radiology.

[114]  Ichio Aoki,et al.  Manganese‐enhanced magnetic resonance imaging (MEMRI): methodological and practical considerations , 2004, NMR in biomedicine.

[115]  Katherine S. Lovejoy,et al.  Water-soluble porphyrins as a dual-function molecular imaging platform for MRI and fluorescence zinc sensing , 2007, Proceedings of the National Academy of Sciences.

[116]  A. Koretsky,et al.  Manganese ion enhances T1‐weighted MRI during brain activation: An approach to direct imaging of brain function , 1997, Magnetic resonance in medicine.

[117]  Thomas J Meade,et al.  Magnetic resonance contrast agents for medical and molecular imaging. , 2004, Metal ions in biological systems.

[118]  D G Cory,et al.  Dynamic nuclear polarization in silicon microparticles. , 2007, Physical review letters.